Ukoniq (Umbralisib)
- Medicine Name: Ukoniq
- Generic Name: Umbralisib
- Dosage Form & Strength: Tablets: 200 mg
- Manufactured By: TG Therapeutics, Inc.
Medical Uses
Ukoniq is a kinase inhibitor used for the treatment of adult patients with:
- Relapsed or refractory marginal zone lymphoma (MZL) who have previously received at least one anti-CD20-based regimen.
- Relapsed or refractory follicular lymphoma (FL) who have previously received at least three lines of systemic therapy.
Recommended Dosage: The recommended dosage is 800 mg taken orally once daily with food until the disease is progressive or unacceptable toxicity occurs. Swallow the tablets whole. Do not chew, crush, break, or cut tablets. The ukoniq dosage is taken persistently each day. In case vomiting occurs, do not take an additional dose of ukoniq; continue with the very next scheduled dose. If a dose of ukoniq is missed, take the missed dose of ukoniq unless it is less than twelve hours until the next scheduled dose.
Warning & Precautions
- Severe, including fatal, infections occurred in patients treated with Umbralisib. Monitor for any new or worsening signs/symptoms of infection. For Grade 3 or 4 infection, withhold Umbralisib until infection has resolved.
- Provide prophylaxis for Pneumocystis jirovecii pneumonia (PJP) during therapy with umbralisib 200 mg. Withhold this therapy in patients with suspected PJP of any grade and permanently interrupt in patients with confirmed PJP.
- Monitor for cytomegalovirus (CMV) infection while on treatment with Umbralisib in patients with a history of cytomegalovirus infection. Consider prophylactic antivirals during treatment to prevent cytomegalovirus infection, including CMV reactivation.
- Severe neutropenia occurred in patients treated with Umbralisib. Monitor neutrophil counts at least every two weeks for the first two months of treatment and at least weekly in patients with neutrophil counts <1 ×10 to power of 9/L (Grade 3-4). Consider supportive care as appropriate.
- Serious diarrhea or non-infectious colitis occurred in patients treated with umbralisib tablets. For patients with severe diarrhea (Grade 3, i.e., > 6 stools daily over baseline) or stool with mucus or blood, abdominal pain, change in bowel habits, or peritoneal signs, withhold Umbralisib treatment until resolved and provide supportive care with antidiarrheals or enteric acting steroids as required.
- Serious hepatotoxicity observed in patients treated with Umbralisib pills. Monitor hepatic function during treatment. For ALT/AST higher than 5 to less than 20 times ULN, withhold therapy until return to less than three times ULN, then resume at a reduced dose.
- Serious cutaneous reactions, including fatal cases of exfoliative dermatitis, observed in patients treated with ukoniq 200 mg tablet. Assess patients for new or worsening cutaneous reactions. Review all concomitant drugs and interrupt any potentially contributing medicines. Evaluate at least on a weekly basis until resolved.
- Based on findings and its mechanism of action, Umbralisib can cause fetal harm if administered to a pregnant woman. Females of reproductive age and males with female partners of reproductive age should use appropriate contraception during therapy and for 30 days after the final dose.
Documentation & Availability
What documents are required to import UKONIQ to India?
UKONIQ (umbralisib) tablets can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is UKONIQ available in India?
UKONIQ (umbralisib tablets) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
UKONIQ can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of UKONIQ (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Toll-Free No: +91-7575883015 or write us at sshealthcare1012@gmail.com for ukoniq tablets price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the UKONIQ (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Ukoniq®?
Umbralisib is Generic Name for the trade name drug Ukoniq®.
What is the Manufacturer Name of Ukoniq®?
Ukoniq® is manufactured by TG Therapeutics, Inc.
Is Ukoniq® approved by the FDA?
Yes, Ukoniq® is approved by the FDA. Date of approval: February 5, 2021.
What is Ukoniq®?
Ukoniq is a type of kinase inhibitor. Also called umbralisib tosylate. It is authorized to treat adult patients with MZL (Marginal Zone Lymphoma) or FL (Follicular Lymphoma) that relapsed or did not improve after treatment with other anticancer therapy.
What is the dosage and form of Ukoniq® supplied?
Ukoniq is supplied as Tablets: 200 mg dosage strength for oral administration.
What are the most common side effects due to Ukoniq®?
Most common side effects due to Ukoniq® include: rash, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, and decreased appetite.
How much does Ukoniq® cost in India?
The ukoniq cost in India is absolutely reasonable. In order to procure this MZL & FL medicine authentically, you can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Ukoniq®?
Store the tablets of Ukoniq at temperature 68°F to 77°F (20 to 25°C). Excursions permitted between temperature 59 and 86°F (15 and 30°C).
What are the Highlights of prescribing information for Ukoniq®?
Click Here to download full Ukoniq prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
